Share on StockTwits

McKesson Corp. (NYSE:MCK)’s share price reached a new 52-week high during trading on Wednesday, reports. The stock traded as high as $173.08 and last traded at $169.09, with a volume of 4,433,006 shares traded. The stock had previously closed at $161.83.

A number of research firms have recently commented on MCK. Analysts at Raymond James upgraded shares of McKesson Corp. from an “outperform” rating to a “strong-buy” rating in a research note to investors on Monday. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of McKesson Corp. in a research note to investors on Thursday, December 26th. They now have a $181.00 price target on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of McKesson Corp. in a research note to investors on Friday, November 29th. They now have a $199.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. McKesson Corp. presently has an average rating of “Buy” and an average target price of $160.92.

McKesson Corp. has a 1-year low of $100.48 and a 1-year high of $166.57. The stock’s 50-day moving average is $161.1 and its 200-day moving average is $137.9. The company has a market cap of $39.007 billion and a price-to-earnings ratio of 27.51.

McKesson Corp. (NYSE:MCK) last announced its earnings results on Thursday, October 24th. The company reported $2.27 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.03 by $0.24. The company had revenue of $33.00 billion for the quarter, compared to the consensus estimate of $32.16 billion. During the same quarter in the prior year, the company posted $1.92 earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts predict that McKesson Corp. will post $8.62 earnings per share for the current fiscal year.

McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.